Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 122

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 122
---
 |
| Lender 7             |     | $     |            72,545 |     |       |                  - |
| Total                |     | $     |         1,820,106 |     | $     |          1,404,090 |
| Derivative liability |     | $     |         1,820,106 |     | $     |          1,404,090 |

9. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company
contains the following classes of capital stock as of December 31, 2024:

Common stock, $ 0.0001 par value; 5,800,000,000 shares
authorized: 21,554,704 shares issued and outstanding.

With respect to each matter submitted to a vote of
stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the
number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution
or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the
Company’s stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 800,000,000 shares
authorized of which 600,000 is designated as Series AA Preferred Stock: 34 shares issued and outstanding as of December 31, 2024: 739,000,000
is designated Series A Preferred Stock of which 10,123,771 shares are outstanding as of December 31, 2024:, 60,000,000 is designated Series
M Preferred Stock of which 29,338 shares are outstanding as of December 31, 2024:, and 20,000 is designated Series NC stock of which 15,007
shares are outstanding as of December 31, 2024.

The abovementioned shares authorized pursuant to the
Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of
Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting
each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences,
qualifications, restrictions, options, conversion rights and other special or relative